CD58:CD2 Axis Targeting for CD28-Negative T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapies, particularly those using anti-PD-1 antibodies, are ineffective for patients with a large fraction of CD28-CD8+ T cells, as these cells are insensitive to treatment, necessitating alternative methods to activate anti-tumor immunity.
Innovation Solution
Targeting the CD58:CD2 axis by disrupting CMTM6 regulation of the PD-L1 protein, enhancing CD2-mediated signaling, or using CD58 mimetics to stimulate immune responses in CD28-CD8+ T cells, potentially combined with PD-1 blockage or adoptive cell transfer, to activate immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-PD-1 antibodies are used for cancer immunotherapy, then immune response is enhanced in patients with CD28+ CD8+ T cells, but treatment effectiveness is lost in patients with CD28- CD8+ T cells
Solution Approach 1:
Instead of blocking PD-1 to enhance immune response, the invention inverts the approach by directly activating CD2 on T cells to stimulate immune response. This alternative pathway bypasses the PD-1 blockade mechanism that fails in CD28- T cells, thereby restoring treatment effectiveness for this patient population.
Solution Approach 2:
The invention changes the activation parameter from PD-1/PD-L1 interaction to CD2/CD58 interaction. By using antibodies or CD58 mimetics that specifically activate CD2, the treatment adapts to work effectively with CD28- T cells, expanding applicability to broader patient populations.
2Reliability
If CD28 expression is required for effective anti-PD-1 therapy, then treatment works for CD28+ patients, but hundreds of thousands of CD28- patients receive no benefit
Solution Approach 1:
The invention introduces CD58 (or CD58 mimetics) as an intermediary that directly activates CD2 on T cells. This intermediary mechanism bypasses the requirement for CD28 expression, allowing therapeutic response in CD28- patients and thereby increasing the number of treatable patients.
Solution Approach 2:
Rather than requiring CD28 expression for therapy to work, the invention inverts the dependency by directly activating CD2 through CD58 engagement. This reversal expands the treatable patient population from those with CD28+ T cells to include CD28- patients as well.
3Ease of operation
If conventional immunotherapy mechanisms are used, then treatment is simple to administer, but it fails to activate CD28- CD8+ T cells
Solution Approach 1:
The invention uses antibodies or CD58 mimetics as intermediaries that can be administered systemically to activate CD2 on T cells. This approach maintains ease of administration through standard injection routes while achieving reliable immune activation in CD28- T cells that conventional therapies cannot activate.
Data Source
AI summary
The method of enhancing anti-tumor immunity in a patient by targeting the CD58:CD2 axis uses an administered treatment to target and disrupt CMTM6 regulation of PD-L1 protein, thus enhancing the immune response and cancer immunotherapy in the patient. Targeting and disruption of CMTM6 regulation of the PD-L1 protein may be combined with additional prompting of a PD-1 blockage or adoptive cell transfer (ACT) in the patient. Targeting and disrupting CMTM6 regulation of PD-L1 protein may be initiated by administering an effective amount of antibodies to the patient, which are specific to disrupting CMTM6/PD-L1 protein interaction. Alternatively, to enhance the anti-tumor immunity in the patient, CD2 mediated signaling may be increased in order to stimulate an immune response. As another alternative to using antibodies or a CD58 mimetic, a pharmacological target to boost CD2/CD58 signaling in the patient may be identified and administered to enhance anti-tumor immunity.